Meridian Co., Ltd.
OTC Bulletin Board : MRDAF

Meridian Co., Ltd.

December 22, 2006 09:00 ET

Meridian Signs $28,000,000 USD Contract for Supply of Digital Pulse Analyzers to US Federal Government-Affiliated Subcontractor

VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - Dec. 22, 2006) - Meridian Co., Ltd. ("Meridian" or the "Company") (OTCBB:MRDAF) an industry leader in the research/development, manufacturing and sales of integrative medical equipment, announced today that it has entered into a definitive contract (the "Contract") for the sale of Digital Pulse Analyzers (DPAs) to Ohio-based Global Health Authority Inc. ("GHA"), through the Company's exclusive North American distributor, British Columbia, Canada-based Meridian Medical Inc. ("MMI"). The Contract incorporates and expands on the terms of the Letter of Intent referred to in the Company's press release of November 20, 2006.

The Contract anticipates the purchase of DPAs by GHA for use in an extensive cardiovascular testing program to be delivered by GHA to various branches of the US armed services worldwide over the five year term of the Contract. GHA is a privately held company whose principals have a wealth of experience in the use of the DPA as a tool in cardiovascular testing programs. GHA has secured a contract for the supply of cardiovascular testing services to the US military through its business relationship with Armco Development, Inc. ("Armco"), a Tennessee-based, prime contract vendor for the World Wide Federal Supply Schedule Contract with the U.S. Department of Defense and Department of Veterans Affairs. Based on unit sale projections from GHA and Armco, the Company expects revenues of between $24,800,000 USD and $28,000,000 USD, depending on volume discounting variables. After payment of agency fees to MMI, the Company's portion of total product revenues under the Contract will be approximately 90%, resulting in potential revenues to the Company during the five year term of the Contract of between $22,320,000 USD and $25,200,000 USD.

More About: Digital Pulse Analyzer ("DPA")

The DPA accurately measures the elasticity of small and large arteries and provides health care practitioners with critical information regarding arterial aging. This FDA-approved device is inexpensive, non-invasive, and can provide results in minutes. Accumulating evidence suggests that abnormalities in the pulsatile characteristics of arteries occur early in the disease process associated with increased cardiovascular risk, and can be favorably modified by therapeutic interventions.

The Company feels that use of the DPA can help caregivers reduce cardiovascular disease in their patient populations through early detection and prevention, and ultimately assist to decrease the associated financial costs placed on the health care industry. Cardiovascular disease is the number one killer in the United States with an estimated economic cost of approximately $298 billion.

More About: Global Health Authority ("GHA")

GHA is an established leader in the sales and training of the Digital Pulse Analyzer. Mr. Al Sewell, a two-time Olympian and fitness advocate, is a financial advisor for ARMCO Development, Inc. as well as Chairman of the Board for GHA. Mr. Sewell has appointed Dr. Harry Elwardt and Nanci Frazer to the GHA team.

Dr. Harry Elwardt, N.D., PhD has accepted the position of President and CEO of GHA. Dr. Elwardt is also the author of the newly published book "Let's STOP the #1 Killer of Americans Today". Dr. Elwardt believes that through early detection, using the DPA, and by following a carefully designed nutritional program, Americans can win the war against heart disease.

Nanci Frazer has joined the GHA corporate team as Vice President and COO. Nanci is a seasoned sales and marketing executive with over 20 years experience in launching and leading numerous companies to success.

More About: Meridian

Meridian is an established leader in the research/development, manufacturing and sales of integrative medical equipment. The Company sells its products and equipment to a wide range of customers in the global health care industry. The Company presently holds a total of 18 worldwide patents on its technology, and has received FDA approval, as well as other international regulatory approvals, for many of its products.

On Behalf of the Board of Directors,

Hyeon Seong Myeong, President

This press release may contain certain forward-looking information and statements concerning the company's operations, performance and financial condition. These statements are based upon a number of uncertainties and contingencies, many of which are beyond the control of the Company. Actual results may differ materially from those expressed or implied by such forward-looking statements. This document is not intended to be and is not an advertisement for any securities of the Company.

Contact Information